ciclosporin 50mg capsules
j m mcgill ltd - ciclosporin - oral capsule - 50mg
ciclosporin 50mg capsules
niche pharma ltd - ciclosporin - oral capsule - 50mg
ciclosporin 50mg capsules
ethigen ltd - ciclosporin - oral capsule - 50mg
ciclosporin 50mg capsules
mawdsley-brooks & company ltd - ciclosporin - oral capsule - 50mg
ciclosporin 50mg capsules
icarus pharmaceuticals ltd - ciclosporin - oral capsule - 50mg
ciclosporin 50mg capsules
ennogen healthcare ltd - ciclosporin - oral capsule - 50mg
ciclosporin 50mg capsules
pharma-z ltd - ciclosporin - oral capsule - 50mg
dexiclo
douglas pharmaceuticals limited - ciclosporin 50mg - soft gelatin capsule - 50 mg - active: ciclosporin 50mg excipient: ethyl lactate gelatin glycerol lecithin medium-chain triglycerides peg-40 castor oil polysorbate 20 purified water sorbitan oleate titanium dioxide - solid organ transplantation: - prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allergenic transplantations. - treatment of transplant rejection in patients previously receiving other immunosuppressive agents.
cyclosporin sandoz ciclosporin 50mg capsules blister pack
novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: propylene glycol; ethanol; glycerol; titanium dioxide; peg-40 hydrogenated castor oil; gelatin; corn glycerides; dl-alpha-tocopherol; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - cyclosporin sandoz is indicated as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see precautions). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with the quality of life. for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate. careful monitoring of all cyclosporin-treated patients is mandatory. cyclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see "precautions").
sporimune 50 mg/ml or. sol.
dechra regulatory b.v. - ciclosporin 50 mg/ml - oral solution - 50 mg/ml - ciclosporin 50 mg/ml - ciclosporin - dog; cat